PON1 and rheumatoid arthritis: To our best knowledge, no other studies have been conducted on the effects of JAK inhibitors, namely those of tofacitinib, on metabolic markers including lipids, adipokines, MPO, PON1 or TSP-1 in association with clinical parameters and vascular pathophysiology as determined by FMD, PWV and IMT in RA.